Grundler P V, Eichler R, Talip Z, Schubiger P A, Schibli R, van der Meulen N P
Center of Radiopharmaceutical Sciences PSI-USZ-ETH, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland.
Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland.
Chimia (Aarau). 2020 Dec 23;74(12):968-975. doi: 10.2533/chimia.2020.968.
Radionuclide production and development has a long history at the Paul Scherrer Institute (PSI) and dates back to the founding times of its forerunner institutions: the Federal Institute for Reactor Research and the Swiss Institute for Nuclear Research. The facilities used for this purpose have evolved substantially over the last five decades. Many radiometals in use today, as radiopharmaceuticals, are for the diagnosis and treatment of disease, with the most popular means of detection being Positron Emission Tomography. These positron emitters are easily produced at low proton energies using medical cyclotrons, however, developments at these facilities are lacking. Currently, the fixed 72 MeV proton beam at PSI is degraded at IP2 irradiation station to provide the desired energy to irradiate targets to produce the likes of Sc, Sc and Cu as a proof of principle, which are of great interest to the nuclear medicine community. This development work can then be implemented at facilities containing medical cyclotrons. A history of the development of radionuclides at PSI, along with current development and projects with partner institutions, is described.
放射性核素的生产与开发在保罗·谢勒研究所（PSI）有着悠久的历史，可以追溯到其前身机构——联邦反应堆研究所和瑞士核研究所的创立时期。在过去的五十年里，用于此目的的设施有了显著的发展。如今，许多用作放射性药物的放射性金属用于疾病的诊断和治疗，最常用的检测手段是正电子发射断层扫描。这些正电子发射体使用医用回旋加速器在低质子能量下很容易产生，然而，这些设施的发展却有所欠缺。目前，PSI的固定72兆电子伏特质子束在IP2辐照站被降低能量，以提供所需能量来辐照靶材，从而生产出钪、钪和铜等作为原理验证，这对核医学界极具吸引力。然后，这项开发工作可以在装有医用回旋加速器的设施中实施。本文描述了PSI放射性核素的发展历程，以及当前与合作机构的开发情况和项目。
